Our findings suggest that the SPON1-TRIM29 fusion gene could contribute to tumor aggressiveness in a population of ovarian cancer and that the new biomarker may be applied as a therapeutic target for fusion-positive tumors. This evidence concerns the gene SPON1 and ovarian cancer.